
Cytonus is a biotechnology company focused on revolutionizing drug discovery and delivery through its proprietary Cargocyte platform. By combining AI, synthetic biology, and advanced drug delivery, Cytonus aims to create more effective and safer medicines. The Cargocyte is a synthetic, enucleated cell-like entity designed to deliver targeted payloads to specific disease sites, mitigating the systemic toxicity often associated with traditional drugs. Their AI-driven approach allows for rapid screening and engineering of therapeutics, addressing the high failure rate in drug development. The company is based in Carlsbad, CA.

Cytonus is a biotechnology company focused on revolutionizing drug discovery and delivery through its proprietary Cargocyte platform. By combining AI, synthetic biology, and advanced drug delivery, Cytonus aims to create more effective and safer medicines. The Cargocyte is a synthetic, enucleated cell-like entity designed to deliver targeted payloads to specific disease sites, mitigating the systemic toxicity often associated with traditional drugs. Their AI-driven approach allows for rapid screening and engineering of therapeutics, addressing the high failure rate in drug development. The company is based in Carlsbad, CA.
Headquarters: Carlsbad / San Diego area
Core technology: Cargocyte — enucleated cell-like delivery platform
Stage (most recent): Advancing toward clinical-stage; completed Series A (Nov 3, 2023)
Total disclosed funding: Approximately $20.94M (reported total) with an $11.7M Series A
Founders: Remo Moomiaie-Qajar, M.D.; Richard Klemke, Ph.D.
Targeted drug delivery and biologic therapeutic development to reduce systemic toxicity and improve efficacy.
2018
Biotechnology
11.7M
Reported lead and participants include Partners Investment, Prox Ventures, Gemseki, Creative Ventures, John Ballantyne, KreaMedica, Wilson Sonsini Goodrich & Rosati
“Participation from institutional and specialized biotech investors including Partners Investment, Prox Ventures, Gemseki, Creative Ventures, John Ballantyne and legal/strategic participant Wilson Sonsini Goodrich & Rosati”